Evidence map›Paper›PMID 25949858›Full record

ReviewOncoimmunology2015

Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.

Oana Draghiciu, Joyce Lubbers, Hans W Nijman, Toos Daemen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

165 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Oana DraghiciuDepartment of Medical Microbiology; Tumor Virology and Cancer Immunotherapy; University of Groningen; University Medical Center Groningen ; Groningen, The Netherlands.
Joyce LubbersDepartment of Medical Microbiology; Tumor Virology and Cancer Immunotherapy; University of Groningen; University Medical Center Groningen ; Groningen, The Netherlands.
Hans W NijmanDepartment of Gynecology; University of Groningen; University Medical Center Groningen ; Groningen, The Netherlands.
Toos DaemenDepartment of Medical Microbiology; Tumor Virology and Cancer Immunotherapy; University of Groningen; University Medical Center Groningen ; Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) contribute to tumor-mediated immune escape and negatively correlate with overall survival of cancer patients. Nowadays, a variety of methods to target MDSCs are being investigated. Based on the intervention stage of MDSCs, namely development, expansion and activation, function and turnover, these methods can be divided into: (I) prevention or differentiation to mature cells, (II) blockade of MDSC expansion and activation, (III) inhibition of MDSC suppressive activity or (IV) depletion of intratumoral MDSCs. This review describes effective mono- or multimodal-therapies that target MDSCs for the benefit of cancer treatment.

Indexed as

5-Fluorouracil5-FU, 5-fluorouracilADAM17, metalloproteinase domain-containing protein 17all-trans retinoic acidAPCs, antigen presenting cellsARG1, arginase-1ATRA, all-trans retinoic acidbisphosphonatesCCL2, chemokine (C-C motif) ligand 2CD62L, L-selectinCDDO-Me, bardoxolone methylc-kit, Mast/stem cell growth factor receptorCOX2, cyclooxygenase 2CTLs, cytotoxic T lymphocytesCXCL12, chemokine (C-X-C motif) ligand 12CXCL15, chemokine (C-X-C motif) ligand 15DCs, dendritic cellsERK1/2, extracellular signal-regulated kinasesFlt3, Fms-like tyrosine kinase 3FoxP3, forkhead box P3gemcitabineGITR, anti-glucocorticoid tumor necrosis factor receptorGM-CSF/CSF2, granulocyte monocyte colony stimulating factorGSH, glutathioneHIF-1α, hypoxia inducible factor 1αHLA, human leukocyte antigenHNSCC, head and neck squamous cell carcinomaHPV-16, human papillomavirus 16HSCs, hematopoietic stem cellsICT, 3, 5, 7-trihydroxy-4′-emthoxy-8-(3-hydroxy-3-methylbutyl)-flavoneIFNγ, interferon γIL-10, interleukin 10IL-13, interleukin 13IL-1β, interleukin 1 βIL-4, interleukin 4IL-6, interleukin 6IMCs, immature myeloid cellsimmune suppressive mechanismsiNOS2, inducible nitric oxid synthase 2JAK2, Janus kinase 2MDSCs, myeloid-derived suppressor cellsMMPs, metalloproteinases (e.g., MMP9)mRCC, metastatic renal cell carcinomaMyd88, myeloid differentiation primary response protein 88myeloid-derived suppressor cellsNAC, N-acetyl cysteineNADPH, nicotinamide adenine dinucleotide phosphate-oxidase NK cells, natural killer cellsNOHA, N-hydroxy-L-ArginineNO, nitric oxideNSAID, nonsteroidal anti-inflammatory drugsODN, oligodeoxynucleotidesPDE-5, phosphodiesterase type 5PGE2, prostaglandin E2RNS, reactive nitrogen speciesROS, reactive oxygen speciesSCF, stem cell factorSTAT3, signal transducer and activator of transcription 3sunitinib therapeutic vaccinationTAMs, tumor-associated macrophagesTCR, T cell receptorTGFβ, transforming growth factor βTNFα, tumor necrosis factor αTregs, regulatory T cellsVEGFR, vascular endothelial growth factor receptorWA, withaferin AWRE, Withaferin somnifera

Identifiers

PMID25949858
PMCPMC4368153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.